Get notified when JBIO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Dilution Per Share to New Investors In This Offering $7.64 (new) — New investors face immediate dilution of $7.64 per share, representing over 50% of the $15.00 offering price, due to the low net tangible book value.
- 12,622,000 Shares of Common Stock Issuable Upon the Conversion of 12,622 Outstanding Shares of Series A Preferred Stock (new) — The conversion of Series A Preferred Stock could add 12.6 million shares, significantly diluting existing and new shareholders.
- 8,777,486 Shares of Common Stock Issuable Upon the Exercise of 8,777,486 Pre-funded Warrants With an Exercise Price of $0.0001 Per Share (new) — Pre-funded warrants with a nominal exercise price are almost certain to be exercised, adding over 8.7 million shares and diluting investors.
- 7,354,734 Shares of Common Stock Issuable Upon the Exercise of Stock Options With a Weighted-average Exercise Price of $4.80 Per Share (new) — A large number of stock options have an exercise price well below the offering price, creating significant potential dilution when exercised.
- 5,294,474 Shares of Common Stock Issuable Upon the Exercise of Stock Options With a Weighted-average Exercise Price of $12.44 Per Share (new) — Additional stock options with exercise prices below the offering price further increase the potential dilution overhang.
Jade Biosciences prices $150M IPO of 10M shares at $15.00 each; net proceeds to company $140.3M
Filed June 4, 2026 · ~2 min read
Key Changes
-
high
Jade Biosciences is offering 10,000,000 shares of common stock at $15.00 per share, with net proceeds to the company of approximately $140.3 million.
The Offering verify on EDGAR → -
high
New investors will incur immediate dilution of $7.64 per share, as the as-adjusted net tangible book value after the offering is approximately $7.52 per share.
Dilution verify on EDGAR → -
medium
The company intends to use net proceeds to fund clinical trials, preclinical studies, manufacturing, and other R&D, with the remainder for working capital and general corporate purposes.
Use of Proceeds verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FUL 10-Q) is open in full — no account needed.
Partner
Trade JBIO commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify